Analytical Data
-
Gene name
HLA-A*02:01&B2M&p53(RMPEAAPPV) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & p53 (RMPEAAPPV)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&RMPEAAPPV
-
Molecular Weight
40-43 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*02:01/B2M/p53 (RMPEAAPPV) monomeric recombinant proteins is rooted in the quest to understand the immune response and cancer immunotherapy. HLA-A*02:01 is a major histocompatibility complex (MHC) class I molecule that presents peptide antigens to CD8+ T cells, facilitating the recognition and eradication of tumor cells. The p53 protein, a key tumor suppressor, regulates the cell cycle and promotes apoptosis; however, mutations in the TP53 gene are common in various cancers, leading to abnormal p53 expression and function. The RMPEAAPPV peptide, derived from the p53 protein, represents an epitope that can elicit a strong immunogenic response in individuals with the HLA-A*02:01 allele. By synthesizing the HLA-A*02:01/B2M/p53 monomer in a recombinant format, researchers aim to explore its structural properties, binding affinities, and the potential for eliciting T cell responses. This research is crucial for the development of targeted cancer vaccines and immunotherapies, as it enhances our understanding of how specific tumor antigens can be presented to the immune system to induce a robust anti-tumor response. Through these studies, we hope to contribute to the advancement of personalized medicine strategies in oncology, paving the way for more effective treatments based on individual genetic profiles.
